LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF BAS VAN DER BAAN, INTERNATIONALLY RECOGNIZED BIOTECH BUSINESS DEVELOPMENT EXECUTIVE, TO ITS BOARD OF DIRECTORS
June 21 2022 - 7:30AM
LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage
pharmaceutical company focused on developing and commercializing
cancer therapies, announced the appointment of Bas van der Baan to
its Board of Directors. He will serve as an independent director.
Dr. John S. Kovach, Founder and Chief Executive
Officer of Lixte, commented, “We are very pleased to welcome Mr.
van der Baan to our Board of Directors. Mr. van der Baan has over
20 years of experience in the biotechnology industry with a key
focus on oncology and diagnostics. He has extensive knowhow in the
journey from clinical development to reimbursement and
commercialization, as well as the establishment of partnerships
with the pharmaceutical industry, academic collaborators,
distributors, insurance companies and governments to successfully
launch new oncology products.”
Dr. Kovach continued, “Lixte is now in the
clinical phase of development of LB-100, its first-in-class protein
phosphatase 2A (PP2A) inhibitor. Our goal is to demonstrate the
potential of this novel anti-cancer compound as a major new
addition to chemotherapy and immunotherapy regimens. Mr. van der
Baan will bring substantial experience and expertise in the
commercialization of new modalities in the oncology market to our
Board of Directors as we continue the clinical development of
LB-100.”
About LIXTE Biotechnology Holdings,
Inc.
LIXTE Biotechnology Holdings, Inc. (Nasdaq:
LIXT), is a clinical-stage pharmaceutical company focused on new
targets for cancer drug development and developing and
commercializing cancer therapies. Major drivers of cancer are
defects in the switches that turn the biochemical pathways in cells
on or off. Most cancer research over the past 30 years has focused
on the “on” switches because the “off” switches, especially the
master “off” switch protein phosphatase (PP2A), were believed to
cause intolerable toxicity in patients. LIXTE has achieved a
breakthrough with its novel, first-in-class lead clinical compound
and PP2A inhibitor, LB-100, demonstrating that LB-100 is readily
tolerated in cancer patients at doses associated with anti-cancer
activity. Based on extensive published preclinical data
(see www.lixte.com), LB-100 has the potential to significantly
improve outcomes for patients undergoing various chemotherapies or
immunotherapies. LIXTE’s new approach has no known competitors and
is covered by a comprehensive patent portfolio. Initial
proof-of-concept clinical trials are in progress.
Forward-Looking Statements
This announcement contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, and Section 21E of the Securities Exchange
Act of 1934. For example, statements regarding the Company's
financial position, business strategy and other plans and
objectives for future operations, and assumptions and predictions
about future product demand, supply, manufacturing, costs,
marketing and pricing factors are all forward-looking statements.
These statements are generally accompanied by words such as
"intend," anticipate," "believe," "estimate," "potential(ly),"
"continue," "forecast," "predict," "plan," "may," "will," "could,"
"would," "should," "expect" or the negative of such terms or other
comparable terminology. The Company believes that the assumptions
and expectations reflected in such forward-looking statements are
reasonable, based on information available to it on the date
hereof, but the Company cannot provide assurances that these
assumptions and expectations will prove to have been correct or
that the Company will take any action that the Company may
presently be planning. However, these forward-looking statements
are inherently subject to known and unknown risks and
uncertainties. Actual results or experience may differ materially
from those expected or anticipated in the forward-looking
statements. Factors that could cause or contribute to such
differences include, but are not limited to, regulatory policies,
available cash, research results, competition from other similar
businesses, and market and general economic factors. This
discussion should be read in conjunction with the Company's filings
with the United States Securities and Exchange Commission
at http://www.sec.gov/edgar.shtml.
Lixte Contact:
info@lixte.comGeneral Phone: (631) 830-7092Investor Phone: (888)
289-5533
Lixte Biotechnology (NASDAQ:LIXT)
Historical Stock Chart
From Apr 2024 to May 2024
Lixte Biotechnology (NASDAQ:LIXT)
Historical Stock Chart
From May 2023 to May 2024